118 related articles for article (PubMed ID: 7541492)
21. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus-mediated expression of human CD55 or CD59 protects adult porcine islets from complement-mediated cell lysis by human serum.
Schmidt P; Goto M; Le Mauff B; Anegon I; Korsgren O
Transplantation; 2003 Mar; 75(5):697-702. PubMed ID: 12640312
[TBL] [Abstract][Full Text] [Related]
23. Primary human hepatocytes are protected against complement by multiple regulators.
Halme J; Sachse M; Vogel H; Giese T; Klar E; Kirschfink M
Mol Immunol; 2009 Jul; 46(11-12):2284-9. PubMed ID: 19446335
[TBL] [Abstract][Full Text] [Related]
24. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells.
Moutabarrik A; Nakanishi I; Namiki M; Hara T; Matsumoto M; Ishibashi M; Okuyama A; Zaid D; Seya T
Lymphokine Cytokine Res; 1993 Jun; 12(3):167-72. PubMed ID: 7688580
[TBL] [Abstract][Full Text] [Related]
25. Species-specific restriction of complement by HRF20 (CD59) generated by cDNA transfection.
Takizawa H; Takahashi K; Murakami T; Okada N; Okada H
Eur J Immunol; 1992 Jul; 22(7):1943-6. PubMed ID: 1378024
[TBL] [Abstract][Full Text] [Related]
26. Functional expression of human CD59 in transgenic mice.
Somerville CA; Kyriazis AG; McKenzie A; Allison J; Pearse MJ; D'Apice AJ
Transplantation; 1994 Dec; 58(12):1430-5. PubMed ID: 7528953
[No Abstract] [Full Text] [Related]
27. Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders.
Roddy J; Clark I; Hazleman BL; Compston DA; Scolding NJ
J Neurol; 1994 Aug; 241(9):557-60. PubMed ID: 7528270
[TBL] [Abstract][Full Text] [Related]
28. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression.
Antel JP; McCrea E; Ladiwala U; Qin YF; Becher B
J Immunol; 1998 Feb; 160(4):1606-11. PubMed ID: 9469416
[TBL] [Abstract][Full Text] [Related]
29. The tetraspanin protein, CD9, is expressed by progenitor cells committed to oligodendrogenesis and is linked to beta1 integrin, CD81, and Tspan-2.
Terada N; Baracskay K; Kinter M; Melrose S; Brophy PJ; Boucheix C; Bjartmar C; Kidd G; Trapp BD
Glia; 2002 Dec; 40(3):350-9. PubMed ID: 12420314
[TBL] [Abstract][Full Text] [Related]
30. Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system?
Raine CS; Wu E; Ivanyi J; Katz D; Brosnan CF
Lab Invest; 1996 Jul; 75(1):109-23. PubMed ID: 8683935
[TBL] [Abstract][Full Text] [Related]
31. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
[TBL] [Abstract][Full Text] [Related]
32. Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice.
Massa PT; Wu C; Fecenko-Tacka K
J Neurosci Res; 2004 Jul; 77(1):15-25. PubMed ID: 15197735
[TBL] [Abstract][Full Text] [Related]
33. Presence of autoantibodies against complement regulatory proteins in relapsing-remitting multiple sclerosis.
Pintér C; Beltrami S; Caputo D; Ferrante P; Clivio A
J Neurovirol; 2000 May; 6 Suppl 2():S42-6. PubMed ID: 10871784
[TBL] [Abstract][Full Text] [Related]
34. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
Storch MK; Piddlesden S; Haltia M; Iivanainen M; Morgan P; Lassmann H
Ann Neurol; 1998 Apr; 43(4):465-71. PubMed ID: 9546327
[TBL] [Abstract][Full Text] [Related]
35. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
Koning N; Swaab DF; Hoek RM; Huitinga I
J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
[TBL] [Abstract][Full Text] [Related]
36. Activation of early components of complement targets myelin and oligodendrocytes in the aged rhesus monkey brain.
Duce JA; Hollander W; Jaffe R; Abraham CR
Neurobiol Aging; 2006 Apr; 27(4):633-44. PubMed ID: 15992964
[TBL] [Abstract][Full Text] [Related]
37. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.
De Nardo C; Fonsatti E; Sigalotti L; Calabrò L; Colizzi F; Cortini E; Coral S; Altomonte M; Maio M
J Cell Physiol; 2002 Feb; 190(2):200-6. PubMed ID: 11807824
[TBL] [Abstract][Full Text] [Related]
38. Myelination by mature ovine oligodendrocytes in vivo and in vitro: evidence that different steps in the myelination process are independently controlled.
Ludwin SK; Szuchet S
Glia; 1993 Aug; 8(4):219-31. PubMed ID: 8406679
[TBL] [Abstract][Full Text] [Related]
39. Studies of autoimmunity in multiple sclerosis.
Whitaker JN; Snyder DS
CRC Crit Rev Clin Neurobiol; 1984; 1(1):45-82. PubMed ID: 6400508
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
Sullivan BL; Knopoff EJ; Saifuddin M; Takefman DM; Saarloos MN; Sha BE; Spear GT
J Immunol; 1996 Aug; 157(4):1791-8. PubMed ID: 8759769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
